Diva Laboratories (ROCO:4153) ROCE %: 14.78% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4153 Diva Laboratories Ltd ROCO:4153
74 GF Score
Price NT$31.25
GF Value NT$38.03
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Diva Laboratories ROCE %?

Diva Laboratories ROCO:4153 -1.88% 74 ROCE % is 14.78% as of Dec. 2025. GuruFocus rates ROCO:4153 with a GF Score™ of 74/100 and a GF Value™ of NT$38.03 (Modestly Undervalued). The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Diva Laboratories's annualized ROCE % for the quarter that ended in Dec. 2025 was 14.78%.

Diva Laboratories  (ROCO:4153) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Diva Laboratories ROCE % Related Terms

Diva Laboratories ROCE % Historical Data

* Premium members only.

The historical data trend for Diva Laboratories's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diva Laboratories ROCE % Chart

Diva Laboratories Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.89 6.76 8.56 11.07 10.44

Diva Laboratories Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.19 12.82 10.70 5.17 14.78
ROCO:4153
74GF Score
Diva Laboratories Ltd ROCO:4153
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Diva Laboratories ROCE % Calculation

Diva Laboratories's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=108.99/( ( (1305.445 - 246.916) + (1353.68 - 323.446) )/ 2 )
=108.99/( (1058.529+1030.234)/ 2 )
=108.99/1044.3815
=10.44 %

Diva Laboratories's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=150.052/( ( (1313.66 - 313.485) + (1353.68 - 323.446) )/ 2 )
=150.052/( ( 1000.175 + 1030.234 )/ 2 )
=150.052/1015.2045
=14.78 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 14.78% mean?
Diva Laboratories (ROCO:4153) has a ROCE % of 14.78% as of Dec. 2025.
Is Diva Laboratories' ROCE % too high?
Diva Laboratories' current ROCE % is 14.78%. Overall, Diva Laboratories has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diva Laboratories' ROCE % compare to TMO and DHR?
Diva Laboratories' ROCE % of 14.78% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Diagnostics & Research company?
A good ROCE % depends on the Medical Diagnostics & Research industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Diva Laboratories's current ROCE % is 14.78%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diva Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Diva Laboratories (ROCO:4153) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$38.03, compared to a current price of NT$31.25 — trading 17.8% below its estimated fair value. The current ROCE % is 14.78%. Diva Laboratories' overall GF Score™ is 74/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Diva Laboratories (ROCO:4153), the current ROCE % is 14.78% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Diva Laboratories (ROCO:4153) Overvalued in 2026?

Based on GuruFocus' analysis, Diva Laboratories stock appears to be undervalued. The current stock price of NT$31.25 is trading 17.8% below its estimated GF Value™ of NT$38.03. GuruFocus considers Diva Laboratories to be Modestly Undervalued.

Key valuation signals for ROCO:4153:

  • ROCE %: 14.78%
  • GF Value™: NT$38.03 vs. price of NT$31.25 (17.8% below fair value)
  • GF Score™: 74/100 with 2 warning signs

No single metric tells the full story. See the ROCO:4153 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Diva Laboratories Business Description

Address Zhongshan Road, 9th Floor, No.351, Section 2, Zhonghe District, New Taipei City, TWN, 235602
Diva Laboratories Ltd is engaged in the sale, manufacturing and development of medical equipment and computer-related devices. Its products are divided into Medical display which includes radiology, endo/surgical, touch, and embedded display; and Industrial display which includes touch display monitors. It derives revenue from sale of Medical monitors, Medical parts, Industrial monitors, Industrial parts, and Parts. Geographically it operates and derives revenue from Taiwan.
74GF Score

Get the complete analysis for ROCO:4153

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$31.25
Price
NT$38.03
GF Value